Coya Therapeutics Registers 2.52M Shares for Resale by Selling Stockholders, Including Full Exit by Key Partner Dr. Reddy's
COYA sits 15% above its 52-week low of $3.94.
Summary
Coya Therapeutics filed an S-3 registration statement for the resale of 2.52 million shares by selling stockholders, including a full liquidation of shares by strategic partner Dr. Reddy's Laboratories, creating a significant market overhang.
Key Events · Financing and Capital Events · COYA
-
Resale Registration Filed
Coya Therapeutics, Inc. filed an S-3 registration statement for the resale of up to 2,522,727 shares of common stock by selling stockholders.
-
Significant Share Overhang
The shares registered for resale represent approximately 10.75% of the company's outstanding common stock, creating a potential overhang on the stock price.
-
Key Partner Liquidating Stake
Dr. Reddy's Laboratories, Inc., a strategic development and license partner, is registering to sell its entire holding of 2,272,727 shares, which were acquired in a private placement on January 29, 2026.
-
No Proceeds to Company
The company will not receive any proceeds from the sale of these shares by the selling stockholders, as this is a secondary offering.
Analysis · COYA · Life Sciences
This S-3 filing registers 2.52 million shares for resale by existing stockholders, representing a substantial 10.75% of the company's outstanding common stock. While the shares were originally issued in a private placement on January 29, 2026, this registration creates a significant market overhang as these shares can now be sold into the market. Notably, Dr. Reddy's Laboratories, a key development and license partner, is registering to sell its entire 2.27 million share stake, signaling a potential shift in their long-term equity commitment to Coya Therapeutics. The company will not receive any proceeds from these sales, making this a purely dilutive event for existing shareholders.
At the time of this filing, COYA was trading at $4.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.8M. The 52-week trading range was $3.94 to $7.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.